EUCTR2016-004834-11-BG进行中（未招募）1 期
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis
Rottapharm Biotech S.r.l.0 个研究点目标入组 240 人开始时间: 2017年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Signed and dated informed consent obtained before undergoing any trial-specific procedure.
- •2. Male or female aged =18 years.
- •3. Patients with definite RA diagnosis according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
- •4. Disease duration no longer than 1 year (early RA). Disease duration is defined as the patient self-reported duration of signs and symptoms of synovitis (e.g. pain, swelling, tenderness) of any joints.
- •5. Patients must be naïve to any DMARDs (csDMARDs, or bDMARDs, or tsDMARDs), other than hydroxychloroquine, as long as this is discontinued at least 4 weeks prior to the screening visit.
- •6. Patients with at least 6/68 tender and 6/66 swollen joints, of which at least one joint must be in the hand/wrist (to be imaged in patients participating into the MRI sub-study).
- •7. Patients with moderate” disease activity as documented by a Disease Activity Score 28 (DAS28) (C-Reactive Protein – CRP) index score > 3.2.
- •8. Patients with serum C-reactive protein (hsCRP) higher than the upper limit of normal (ULN), i.e. 3 mg/L.
- •9. Patients positive for serum rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibodies (ACPA).
- •10. Willing and able to comply with the scheduled study visits, the treatment plan, and all study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •Medical history and Concomitant diseases:
- •1. Functional class IV of Global Functional Status (GFS) in RA, as defined by the ACR Classification.
- •2. Rheumatic autoimmune disease other than RA, i.e. systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or Felty's syndrome).
- •3. Current inflammatory joint disease other than RA.
- •4. Non-inflammatory type of musculoskeletal condition (e.g., osteoarthritis or fibromyalgia) that in the Investigator's opinion is symptomatic and/or severe enough to interfere with the subject's primary diagnosis of RA or the evaluation of the effect of the study drug.
- •5. History of gastric/duodenal ulcers and gastrointestinal bleeding.
- •6. Gastrointestinal diseases known to interfere with the absorption or excretion of medications.
- •7. Severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
- •8. Malignancy (with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ) active during the 12 months preceding the Screening Visit.
- •9. Acute hepatitis (during the 3 months preceding the Screening Visit), chronic hepatitis (previous documented diagnosis of viral or autoimmune hepatitis, or detection of any unexplained elevation of serum ALT or AST greater than 1.5-fold ULN, at least twice in the 6 months before the Screening Visit) and HIV infection.
- •10. History of alcohol or drug abuse during the 12 months preceding the Screening Visit.
- •11. Allergy/hypersensitivity/intolerance to any components in CR6086
- •and MTX, including excipients such as lactose (patients with rare
- •hereditary problems of galactose intolerance, Lapp lactase deficiency, or
- •glucose-galactose malabsorption should be excluded), starch,
- •magnesium stearate, cellulose.
- •12. Vaccination with live vaccines during the 6 weeks preceding the Screening Visit.
- •Laboratory and examinations
- •13. Hemoglobin <9 g/dL or Hematocrit <30%
- •14. White blood cell (WBC) count <3.0 x 10^9/L
- •15. Absolute neutrophil count <1.2 x 10^9/L
- •16. Platelet count <100 x 10^9/L
- •17. Serum alkaline-phosphatase, or gamma-glutamyl-transferase greater than 3-fold ULN; alanine aminotransferase, or aspartate aminotransferase, or total bilirubin greater than 2-fold ULN.
- •18. Estimated creatinine clearance less than 60 mL/min/1.73 m2 (MDRD).
- •19. 12-lead electrocardiogram (ECG) with clinically relevant findings, as judged by the Investigator.
- •Medications
- •20. Use of hydroxychloroquine during the 4 weeks preceding the Screening Visit.
- •21. Treatment with oral corticosteroids, unless maintained at doses equivalent to =10 mg/day prednisone =7 days before the Screening Visit. Use of steroids by other administration route before screening visit is allowed, with the exception of i.a. administration during the four weeks preceding the screening visit.
- •22. Use of non-ster
研究者
相似试验
进行中（未招募）
1 期
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritisRheumatoid ArthritisEUCTR2016-004834-11-DKRottapharm Biotech S.r.l.240
进行中（未招募）
1 期
Pharmacokinetics of adalimumab after microneedle injectioEUCTR2018-001533-41-NLeiden University Medical Center24
进行中（未招募）
1 期
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritisMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-004834-11-CZRottapharm Biotech S.r.l.240
已完成
不适用
A randomized, double blind, placebo-controlled, double-dummy study to assess microneedle delivery in comparison to subcutaneous injection of adalimumab in healthy volunteersRoute of administrationRoute of administration for immunosuppressive drug10027665NL-OMON46242eids Universitair Medisch Centrum24
进行中（未招募）
1 期
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 180 mg bid for 12 weeks in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritisMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2016-004834-11-PLRottapharm Biotech S.r.l.240